Pharma Focus America

Dewpoint Therapeutics Collaborates with Chemify to Utilize Advanced AI for Accelerating the Discovery of Molecules Targeting Cancer and Neurodegenerative Conditions

Wednesday, September 13, 2023

Dewpoint Therapeutics and Chemify have announced a joint partnership aimed at developing a portfolio of digitally discovered and automatically synthesized novel molecules. These molecules will be designed to target specific condensate-related objectives within Dewpoint's oncology and neurodegeneration research pipelines, using Chemify's programmable chemistry platform.

In this partnership, Chemify's advanced chemistry AI and automation technology platform, which can design, discover, and synthesize complex molecules using a chemical programming language, will join forces with Dewpoint's unique condensate biology and AI technology platform. Chemify, which recently secured $43 million in funding, has created an automated platform for molecular design, discovery, and synthesis, and it will play a pivotal role in enhancing and accelerating Dewpoint's ongoing chemistry projects.

As part of their collaboration, Chemify will be responsible for the design and delivery of new compounds to bolster Dewpoint's advanced research efforts in oncology and neurodegeneration. Dewpoint retains the option to acquire the compounds developed by Chemify, and in return, Chemify will receive predetermined milestones linked to clinical and regulatory success, along with tiered royalty payments.

Ameet Nathwani, M.D., CEO at Dewpoint, expressed, Our partnership with Chemify introduces an innovative approach to leverage our unique chemical assets that are currently undergoing optimization. We aim to harness Chemify's cutting-edge digital chemistry AI-powered concepts to explore new frontiers in drug discovery. We're thrilled to collaborate with Chemify, a leader in this field.

Professor Lee Cronin, CEO of Chemify and Regius Professor of Chemistry at the University of Glasgow, commented, We are extremely excited about this partnership, which combines Chemify's technology for molecular design, discovery, and synthesis with Dewpoint's condensate biology approach to create a seamless drug discovery and design platform. It is truly inspiring to apply the Chemify technology I have been developing for 15 years to positively impact the lives of patients.

Condensates are membraneless organelles that dynamically form within cells through a process called phase separation. These subcellular compartments organize and concentrate molecules within cells, facilitating crucial biochemical processes. Dysregulation of biomolecular condensates has been observed in numerous diseases, including cancer, diabetes, and neurological disorders. Dewpoint's platform has identified disease-associated condensates and developed drugs that can modify these condensates, potentially offering new therapeutic options for complex diseases and historically challenging drug targets.

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024